相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study
Emanuele Cozzani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis
Ming-Ying Wu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The pre- and post-authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
N. Ghalandari et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study
Nicole Salame et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
Youssef A. Elnabawi et al.
CARDIOVASCULAR RESEARCH (2019)
Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence
Maria Mouyis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus
Dimitrios Rigopoulos et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis
Moa P. Lee et al.
JAMA DERMATOLOGY (2019)
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed
Grace Kimmel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
Amit Khatri et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
Stine Timmermann et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study
Leena Chularojanamontri et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis
Kerasia-Maria Plachouri et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
Esther von Stebut et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials
Jeffrey R. Curtis et al.
RMD OPEN (2019)
Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
Chong Won Choi et al.
ANNALS OF DERMATOLOGY (2018)
Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study
S. Tzaneva et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Psoriasis and the metabolic syndrome
Paolo Gisondi et al.
CLINICS IN DERMATOLOGY (2018)
Erythrodermic psoriasis and secukinumab: Our clinical experience
Almudena Mateu-Puchades et al.
DERMATOLOGIC THERAPY (2018)
Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study
Arvin Ighani et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2018)
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study
Shigetoshi Sano et al.
JOURNAL OF DERMATOLOGY (2018)
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Mark G. Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
Boni E. Elewski et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study
K. B. Gordon et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials
Peter Foley et al.
JAMA DERMATOLOGY (2018)
Pregnancy Outcomes After Exposure to Certolizumab Pegol Updated Results From a Pharmacovigilance Safety Database
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study
Akimichi Morita et al.
JOURNAL OF DERMATOLOGY (2018)
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
Xavier Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
K. B. Gordon et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
K. Yamasaki et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
The toxicity of methotrexate in male fertility and paternal teratogenicity
Jennifer Christine Gutierrez et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
D. Thaci et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis
Fernanda Genre et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate
Jashin J. Wu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Liver injury associated with dimethyl fumarate in multiple sclerosis patients
Monica A. Munoz et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies
Christopher E. M. Griffiths et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2017)
Liver injury associated with dimethyl fumarate in multiple sclerosis patients
Monica A. Munoz et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium)
Siegfried Segaert et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series
M. J. van Geel et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Severe Drug-Induced Liver Injury Related to Therapy With Dimethyl Fumarate
Christoph Juengst et al.
HEPATOLOGY (2016)
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
Shinichi Imafuku et al.
JOURNAL OF DERMATOLOGY (2016)
Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists
Chun-Ying Wu et al.
MEDICINE (2016)
Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study
Astrid Schmieder et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2015)
Erythrodermic psoriasis treated with usteldnumab: An Italian multicenter retrospective analysis
Leonardo Pescitelli et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2015)
Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials
Richard Conway et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis
Der-Yuan Chen et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Treatment of Nail Psoriasis Best Practice Recommendations From the Medical Board of the National Psoriasis Foundation
Jeffrey J. Crowley et al.
JAMA DERMATOLOGY (2015)
Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review
P. Fleming et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Lactation and the Use of Biologic Immunosuppressive Medications
Sarah J. Witzel
BREASTFEEDING MEDICINE (2014)
The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial
Nawaf Al-Mutairi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia
Siew Eng Choon et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2014)
Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study
E. Mahe et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Influence of ustekinumab on body weight of patients with psoriasis: an initial report
Agnieszka Owczarczyk-Saczonek et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2014)
Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The Effect of Acitretin Treatment on Insulin Resistance, Retinol-Binding Protein-4, Leptin, and Adiponectin in Psoriasis Vulgaris: A Noncontrolled Study
Ayse Serap Karadag et al.
DERMATOLOGY (2013)
Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study
Hajnalka Jokai et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review
E. Sbidian et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
Tumor Necrosis Factor α Blockers and Malignancy in Children Forty-Eight Cases Reported to the Food and Drug Administration
Peter Diak et al.
ARTHRITIS AND RHEUMATISM (2010)
High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice
Jean-Hilaire Saurat et al.
DERMATOLOGY (2010)
Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation
Misha Rosenbach et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
分享论文
